Medipal Holdings Corporation · TSE:7459
Medipal — FY2022 Earnings Presentation
28 slides from Medipal's earnings presentation, May 12, 2023
Slide 1: Financial Results for the Fiscal Year Ended Mar. 31, 2023
Financial Results for the Fiscal Year Ended Mar. 31, 2023 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being and to enhance its corporate value. May 12, 2023 Forward-Looking Sta
Slide 2: Realizing a society of physical and mental well-being: Constant Innovation
We aim to realize a society in which everyone can live with physical and mental well-being and to enhance our corporate value, and are expanding our business in the fields of “Pharmaceuticals, Health, and Beauty.” ~ Constant Innovation ~ Dec. 1, 2022 Launched operations of MEDISKET CORPORATION, a lo
Slide 3: Contents
Contents 1. Results for the Fiscal Year Ended Mar. 31, 2023 2. Initiatives Based on the 2027 MEDIPAL Medium-Term Vision, “Change the Oroshi Forever—Constant Innovation” 3. Forecast of Consolidated Results and Dividend for the Fiscal Year Ending Mar. 31, 2024 4. Capital Policy・Shareholder Returns Cop
Slide 4: Consolidated Statements of Income
Consolidated Statements of Income ■Sales and profit up ■Sales and each stage profits exceeded earnings forecasts ■Net income increased significantly due to gains on sales of investment securities FY Ended Mar. 31, FY Ended Mar. 31, (\ billion) 2022 2023 Results Plan Results YoY Change Change from Pl
Slide 5: Prescription Pharmaceutical Wholesale Business (MEDICEO Business)
Prescription Pharmaceutical Wholesale Business (MEDICEO Business) ■Net sales were almost unchanged from the previous fiscal year, partly due to the impact of NHI drug price revisions■Gross profit increased due to COVID-19 related profit FY Ended Mar. 31, FY Ended Mar. 31, (\ billion) 2022 2023 Resul
Slide 6: New Businesses
New Businesses ■ Although some contracts delayed in PFMⓇ , almost as planed FY Ended Mar. 31, FY Ended Mar. 31, (\ billion) 2021 2022 FY Ended Mar. 31, 2023 Results Results Plan Results AR 1.7 1.6 1.5 1.5 PFM® 4.8 7.8 8.0 7.8 PMS 0.3 0.1 0.2 0.5 Digital business, others ▲0.4 ▲0.4 ▲0.3 ▲0.5 Total* (G
Slide 7: Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business)
Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business) ■ Increased sales of cosmetics and pharmaceutical products due to the increased number of people going out ■ Profits decreased owing to impact of low-price intention due to soaring prices and temporary expenses
Slide 8: Animal Health Products and Food Processing Raw Materials Wholesale (AGRO・FOOD Business)
Animal Health Products and Food Processing Raw Materials Wholesale and Related Business (AGRO・ FOOD Business) ■ AGRO: Difficult business environment due to bird flu and soaring feed prices ■ Expenses related to make a subsidiary, MP Gokyo Food & Chemical FY Ended Mar. 31, FY Ended Mar. 31, (\ billio
Slide 9: Contents
Contents 1. Results for the Fiscal Year Ended Mar. 31, 2023 2. Initiatives Based on the 2027 MEDIPAL Medium-Term Vision, “Change the Oroshi Forever—Constant Innovation” 3. Forecast of Consolidated Results and Dividend for the Fiscal Year Ending Mar. 31, 2024 4. Capital Policy・Shareholder Returns Cop
Slide 10: Actively Implementing the Five Growth Strategies
Initiatives Based on the Medium-Term Vision Actively Implementing the Five Growth Strategies Based on the Human Resource Strategy and the Financial Strategy The first half of the Medium-Term Vision is the stage of up-front investment in growth Copyright © 2023 MEDIPAL HOLDINGS CORPORATION, All right
Slide 11: Growth Strategy (1) Expansion of Overseas Business
Growth Strategy (1) Expansion of Overseas Business Initiatives Targeting Global Business Expansion Collaboration with JCR Pharmaceuticals Co., Ltd. on global development of new drugs in the ultra-rare disease fields ■ Concluded an agreement with JCR Pharmaceuticals Co., Ltd. on global commercializat
Slide 12: Growth Strategy (2) Expansion of Prevention and Pre-disease Business and AGRO & FOOD Business
Growth Strategy (2) Expansion of Prevention and Pre-disease Business and AGRO & FOOD Business Expansion of the Business Base in the Food Domain Acquisition of all shares of Sumitomo Pharma Food & Chemical Co., Ltd.* from Sumitomo Pharma Co., Ltd. * Corporate name changed from Sumitomo Pharma Food &
Slide 13: Growth Strategy (3) Enhancement of Business with and in Digital
Growth Strategy (3) Enhancement of Business with and in Digital Initiatives Aimed at Building a Top-Level Digital Platform in Japan Creating new businesses by combining the business resources of MEDIPAL and partner companies ■ Child-rearing DX (pediatric immunization): Digitization of medical examin
Slide 14: Growth Strategy (4) Building Sustainable Logistics
Growth Strategy (4) Building Sustainable Logistics Optimizing the Supply of Pharmaceuticals, Clinical Testing Materials, and Other Items, as Well as the Collection of Test Specimens from Clinical Laboratories, Clinical Trials, and Research Japan’s largest healthcare logistics platform supporting “Ph
Slide 15: Revitalization of Nichi-Iko Pharmaceutical Co., Ltd.
Growth Strategy (4) Building Sustainable Logistics Building a System for the Stable Supply of Quality Generic Drugs Revitalization of Nichi-Iko Pharmaceutical Co., Ltd. (Silent Partnership Investment) ■ Will cooperate in supporting J. Will Partners’ (JWP) business revitalization of Nichi-Iko Pharmac
Slide 16: Acquisition of all shares of Toshichi Inc.
Growth Strategy (4) Building Sustainable Logistics Fortifying Distribution Infrastructure in Nagasaki and Saga Region and Building Strong Core Businesses Acquisition of all shares of Toshichi Inc. ■ Built close relationships with business partner, with a history of more than 110 years Nagasaki and S
Slide 17: Growth Strategy (5) Value Co-creation in Community Healthcare
Growth Strategy (5) Value Co-creation in Community Healthcare Development of Marketing Activities for Specialized Fields Resolving healthcare issues as a Regional Medical Coordinator ■ Utilizing human resources with specialized knowledge to implement initiatives that contribute to patients and the l
Slide 18: Investment in Domestic and International Startups
Expansion of the Earnings Base through Investment in Domestic and International Startups ■ Actively investment in promising startups through the MEDIPAL Innovation Fund ■Invested in eight startup companies by Mar. 2023 May 2022 Chordia Therapeutics Inc. Biotech startup company specializing in R&D on
Slide 19: PALTAC Business: Initiatives to Optimize Efficiency
PALTAC Business Initiatives to Optimize and Efficiency in deal with the Working Depopulation Planogram work optimization for attractive sales floors ■ Taking on the Challenge of Automating Planogram Work in Retail Stores with a Large Work Burden in Collaboration with an IT Company ⇒ Allocate resourc
Slide 20: Contents
Contents 1. Results for the Fiscal Year Ended Mar. 31, 2023 2. Initiatives Based on the 2027 MEDIPAL Medium-Term Vision, “Change the Oroshi Forever—Constant Innovation” 3. Forecast of Consolidated Results and Dividend for the Fiscal Year Ending Mar. 31, 2024 4. Capital Policy・Shareholder Returns Cop
Slide 21: Forecast of Results for the Fiscal Year Ending Mar. 31, 2024
Forecast of Results for the Fiscal Year Ending Mar. 31, 2024 (※1) (※2) (\ billion) Consolidated MEDICEO Business PALTAC Business AGRO・FOOD Business YoY YoY YoY YoY （% of Net （% of Net （% of Net （% of Net Sales） Sales） Sales） Sales） Net 3,510.0 +4.5% 2,256.0 +3.0% 1,142.0 +3.4% 116.0 +56.9% Sales Gro
Slide 22: 4. Capital Policy・Shareholder Returns
Contents 1. Results for the Fiscal Year Ended Mar. 31, 2023 2. Initiatives Based on the 2027 MEDIPAL Medium-Term Vision, “Change the Oroshi Forever—Constant Innovation” 3. Forecast of Consolidated Results and Dividend for the Fiscal Year Ending Mar. 31, 2024 4. Capital Policy ・Shareholder Returns Co
Slide 23: Basic Capital Policy
Basic Capital Policy Basic capital policy To strive for sustainable corporate growth and maximization of corporate value through business and financial activities founded on the dual focus of increasing return on equity and reducing the cost of capital In order to generate profits that exceed the
Slide 24: Basic Policies on Strategic Shareholdings and Distribution of Profits
Basic Policies on Strategic Shareholdings and Distribution of Profits Based on the “Basic capital policy”, revised our basic policies regarding strategic shareholdings and distribution of profits Basic policy on Strategic shareholdings To reduce these shareholdings in the interest of controlling sha
Slide 25: Acquisition of Treasury Stock and Cancellation of Treasury Stock
Acquisition of Treasury Stock and Cancellation of Treasury Stock Basic policy on profit distribution (excerpt) will comprehensively assess demand for funding and flexibly implement share buybacks and cancellations of shares as appropriate for the purpose of improving capital efficiency and further r
Slide 26: Dividend for FY Ended Mar. 2023 and Forecast for FY Ending Mar. 2024
Dividend for the FY Ended Mar. 31, 2023 and Dividend Forecast for the FY Ending Mar. 31, 2024 Basic policy on profit distribution (excerpt) In principle, will maintain or increase its dividend payout ratio on earnings before amortization of goodwill and amortization of intangible assets arising from
Slide 27: Total Shareholder Return Ratio in line with 2027 Medium-Term Vision
Total Shareholder Return Ratio in line with 2027 MEDIPAL Medium-Term Aim to achieve a total shareholder return ratio of 40% that is applied to earnings before amortization of goodwill and intangible assets arising from the growth investments set forth in the Medium-Term Vision the five-year cumulati
Slide 28: Contributing to people’s health and the advancement of society
Contributing to people’s health and the advancement of society through creation of value in distribution 28